Abstract
Congenital mesoblastic nephroma is a kidney tumor with potentially malignant behavior originating from spindled mesenchymal cells. It is also known as mesoblastic nephroma (previously named fetal renal hamartoma leiomyomatous renal hamartoma).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Notes
- 1.
ETV6-NTRK3 fusion gene: ETV6 encodes an ETS family transcription factor associated with leukemia and congenital fibrosarcoma. NTRK3 encodes neurotrophic receptor tyrosine kinase 3 and belongs to the tropomyosin receptor kinases (TRK) family which also includes NTRK1 (encoding neurotrophic receptor tyrosine kinase 1) and NTRK2 (neurotrophic receptor tyrosine kinase 2). The encoded proteins elicit activities that regulate the natural growth, differentiation, and survival of neurons when they interact with endogenous neutrotrophin ligands. Chromosomal rearrangements involving in-frame fusions of these genes with various partners, translocations in the TRK kinase domains, mutations in the TRK ligand-binding site, amplifications of NTRK, or the expression of TRK splice variants can result in constitutively activated chimeric TRK fusion proteins that can act as oncogenic drivers that promote cell proliferation and survival in tumor cell lines.
- 2.
Larotrectinib: tyrosine kinase inhibitor targeting the following—NTRK1, NTRK2, NTRK3.
- 3.
Entrectinib: tyrosine kinase inhibitor targeting the following—NTRK1, NTRK2, NTRK3, ROS1, ALK.
Suggested Readings
AACR (2020) Entrectinib OK’d for cancers with NTRK fusions, NSCLC. Cancer Discov 9(10):OF2
Albert (2019) TRK fusion cancers in children: a clinical review and recommendations for screening. J Clin Oncol 37(6):513–524
Al-Salama (2019) Entrectinib: first global approval. Drugs 79(13):1477–1483
Church (2018) Recurrent EML4-NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy. Mod Pathol 31(3):463–473
El Demellawy (2016) Congenital mesoblastic nephroma: a study of 19 cases using immunohistochemistry and ETV6-NTRK3 fusion gene rearrangement. Pathology 48(1):47–50
Farago (2020) Larotrectinib, a selective tropomyosin receptor kinase inhibitor for adult and pediatric tropomyosin receptor kinase fusion cancers. Future Oncol 16(9):417–425
Gooskens (2017) Congenital mesoblastic nephroma 50 years after its recognition: a narrative review. Pediatric Blood Cancer 64(7):e26437
Halalsheh (2018) Dramatic bone remodeling following larotrectinib administration for bone metastasis in a patient with TRK fusion congenital mesoblastic nephroma. Pediatr Blood Cancer 65(10):e27271
Hong (2020) Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol [Epub ahead of print]. https://doi.org/10.1016/S1470-2045(19)30856-3
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2021 The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Mocellin, S. (2021). Congenital Mesoblastic Nephroma. In: Soft Tissue Tumors . Springer, Cham. https://doi.org/10.1007/978-3-030-58710-9_56
Download citation
DOI: https://doi.org/10.1007/978-3-030-58710-9_56
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-58709-3
Online ISBN: 978-3-030-58710-9
eBook Packages: MedicineMedicine (R0)